Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke

Bibliographic Details
Main Author: Bernardo-Castro, S
Publication Date: 2021
Other Authors: Albino, I, Barrera-Sandoval, ÁM, Tomatis, F, Sousa, JA, Martins, E, Simões, S, Lino, MM, Ferreira, L, Sargento-Freitas, J
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.4/2335
Summary: Stroke represents the second leading cause of mortality and morbidity worldwide. Ischemic strokes are the most prevalent type of stroke, and they are characterized by a series of pathological events prompted by an arterial occlusion that leads to a heterogeneous pathophysiological response through different hemodynamic phases, namely the hyperacute, acute, subacute, and chronic phases. Stroke treatment is highly reliant on recanalization therapies, which are limited to only a subset of patients due to their narrow therapeutic window; hence, there is a huge need for new stroke treatments. Nonetheless, the vast majority of promising treatments are not effective in the clinical setting due to their inability to cross the blood-brain barrier and reach the brain. In this context, nanotechnology-based approaches such as nanoparticle drug delivery emerge as the most promising option. In this review, we will discuss the current status of nanotechnology in the setting of stroke, focusing on the diverse available nanoparticle approaches targeted to the different pathological and physiological repair mechanisms involved in each of the stroke phases.
id RCAP_1f84bd4ac902f9fdb6380617bb69a4a8
oai_identifier_str oai:rihuc.huc.min-saude.pt:10400.4/2335
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Therapeutic Nanoparticles for the Different Phases of Ischemic StrokeAVC IsquémicoNanopartículasIschemic StrokeNanoparticlesStroke represents the second leading cause of mortality and morbidity worldwide. Ischemic strokes are the most prevalent type of stroke, and they are characterized by a series of pathological events prompted by an arterial occlusion that leads to a heterogeneous pathophysiological response through different hemodynamic phases, namely the hyperacute, acute, subacute, and chronic phases. Stroke treatment is highly reliant on recanalization therapies, which are limited to only a subset of patients due to their narrow therapeutic window; hence, there is a huge need for new stroke treatments. Nonetheless, the vast majority of promising treatments are not effective in the clinical setting due to their inability to cross the blood-brain barrier and reach the brain. In this context, nanotechnology-based approaches such as nanoparticle drug delivery emerge as the most promising option. In this review, we will discuss the current status of nanotechnology in the setting of stroke, focusing on the diverse available nanoparticle approaches targeted to the different pathological and physiological repair mechanisms involved in each of the stroke phases.RIHUCBernardo-Castro, SAlbino, IBarrera-Sandoval, ÁMTomatis, FSousa, JAMartins, ESimões, SLino, MMFerreira, LSargento-Freitas, J2022-09-19T09:05:05Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.4/2335eng10.3390/life11060482info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-01-30T03:22:12Zoai:rihuc.huc.min-saude.pt:10400.4/2335Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T19:44:29.732876Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke
title Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke
spellingShingle Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke
Bernardo-Castro, S
AVC Isquémico
Nanopartículas
Ischemic Stroke
Nanoparticles
title_short Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke
title_full Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke
title_fullStr Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke
title_full_unstemmed Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke
title_sort Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke
author Bernardo-Castro, S
author_facet Bernardo-Castro, S
Albino, I
Barrera-Sandoval, ÁM
Tomatis, F
Sousa, JA
Martins, E
Simões, S
Lino, MM
Ferreira, L
Sargento-Freitas, J
author_role author
author2 Albino, I
Barrera-Sandoval, ÁM
Tomatis, F
Sousa, JA
Martins, E
Simões, S
Lino, MM
Ferreira, L
Sargento-Freitas, J
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv RIHUC
dc.contributor.author.fl_str_mv Bernardo-Castro, S
Albino, I
Barrera-Sandoval, ÁM
Tomatis, F
Sousa, JA
Martins, E
Simões, S
Lino, MM
Ferreira, L
Sargento-Freitas, J
dc.subject.por.fl_str_mv AVC Isquémico
Nanopartículas
Ischemic Stroke
Nanoparticles
topic AVC Isquémico
Nanopartículas
Ischemic Stroke
Nanoparticles
description Stroke represents the second leading cause of mortality and morbidity worldwide. Ischemic strokes are the most prevalent type of stroke, and they are characterized by a series of pathological events prompted by an arterial occlusion that leads to a heterogeneous pathophysiological response through different hemodynamic phases, namely the hyperacute, acute, subacute, and chronic phases. Stroke treatment is highly reliant on recanalization therapies, which are limited to only a subset of patients due to their narrow therapeutic window; hence, there is a huge need for new stroke treatments. Nonetheless, the vast majority of promising treatments are not effective in the clinical setting due to their inability to cross the blood-brain barrier and reach the brain. In this context, nanotechnology-based approaches such as nanoparticle drug delivery emerge as the most promising option. In this review, we will discuss the current status of nanotechnology in the setting of stroke, focusing on the diverse available nanoparticle approaches targeted to the different pathological and physiological repair mechanisms involved in each of the stroke phases.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01T00:00:00Z
2022-09-19T09:05:05Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.4/2335
url http://hdl.handle.net/10400.4/2335
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.3390/life11060482
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833598295862149120